Evidence map›Paper›PMID 30529930›Full record

Trial reportAmerican heart journal2019

Sex differences in management and outcomes of patients with stable symptoms suggestive of coronary artery disease: Insights from the PROMISE trial.

Neha J Pagidipati, Adrian Coles, Kshipra Hemal, Kerry L Lee, Rowena J Dolor, Patricia A Pellikka, Daniel B Mark, Manesh R Patel, Sheldon E Litwin, Melissa A Daubert and 4 more

Open access · greenAbstract readMulticenter StudyPragmatic Clinical TrialRandomized Controlled Trial
In one paragraph

Trial report in American heart journal, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.5field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 29 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Article
  7. Article
  8. Observational
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 1 country.

Neha J PagidipatiDuke Clinical Research Institute, Duke University School of Medicine, Durham, NC. Electronic address: neha.pagidipati@dm.duke.edu.
Adrian ColesDuke Clinical Research Institute, Duke University School of Medicine, Durham, NC.
Kshipra HemalDuke Clinical Research Institute, Duke University School of Medicine, Durham, NC.
Kerry L LeeDuke Clinical Research Institute, Duke University School of Medicine, Durham, NC.
Rowena J DolorDuke Clinical Research Institute, Duke University School of Medicine, Durham, NC; Department of Medicine, Duke University School of Medicine, Durham, NC.
Patricia A PellikkaMayo Clinic, Rochester, MN.
Daniel B MarkDuke Clinical Research Institute, Duke University School of Medicine, Durham, NC.
Manesh R PatelDuke Clinical Research Institute, Duke University School of Medicine, Durham, NC.
Sheldon E LitwinDepartment of Medicine, Medical University of South Carolina, Charleston, SC.
Melissa A DaubertDuke Clinical Research Institute, Duke University School of Medicine, Durham, NC.
Svati H ShahDuke Clinical Research Institute, Duke University School of Medicine, Durham, NC; Department of Medicine, Duke University School of Medicine, Durham, NC.
Udo HoffmannMassachusetts General Hospital, Harvard Medical School, Boston, MA.
Pamela S DouglasDuke Clinical Research Institute, Duke University School of Medicine, Durham, NC.
PROMISE Investigators
Duke University · USClinical Research Institute · USMassachusetts General Hospital · USMayo Clinic in Arizona · USMedical University of South Carolina · US

Funding

Clinical and Translational Science Collaborative of ClevelandUL1TR002548 · NCATS · CASE WESTERN RESERVE UNIVERSITY · PI MCCOMSEY, GRACE A · 2018 to 2022
$35.5M
PROMISE Trial: Clinical Coordinating CenterR01HL098237 · NHLBI · DUKE UNIVERSITY · PI DOUGLAS, PAMELA SUSAN · 2009 to 2014
$27.3M
Postdoctoral Training in Cardiovascular Clinical ResearchT32HL069749 · NHLBI · DUKE UNIVERSITY · PI MARK, DANIEL B · 2003 to 2023
$6.7M
PROMISE Trial: SDCCR01HL098236 · NHLBI · DUKE UNIVERSITY · PI LEE, KERRY L · 2009 to 2014
$5.0M
PROMISE Trial: Dx CoreR01HL098305 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI HOFFMANN, UDO · 2009 to 2014
$3.5M
PROMISE Trial: EQOL Coordinating CenterR01HL098235 · NHLBI · DUKE UNIVERSITY · PI MARK, DANIEL B · 2009 to 2014
$1.6M
NCATS NIH HHS UL1 TR002548NHLBI NIH HHS R01 HL098235NHLBI NIH HHS R01 HL098236NHLBI NIH HHS R01 HL098237NHLBI NIH HHS R01 HL098305NHLBI NIH HHS T32 HL069749
6 · The paper itself

Abstract

backgroundAlthough sex differences exist in the management of acute coronary syndromes, less is known about the management and outcomes of women and men with suspected coronary artery disease being evaluated with noninvasive testing (NIT).

methodsWe investigated sex-based differences in NIT results and subsequent clinical management in 4,720 women and 4,246 men randomized to CT angiography versus stress testing in the PROMISE trial. Logistic regression models assessed relationships between sex and referral for catheterization, revascularization, and aspirin or statin use. Cox regression models assessed the relationship between sex and the composite of all-cause death, myocardial infarction, or unstable angina.

resultsWomen more often had normal NITs than men (61.0% vs 49.6%, P < .001) and less often had mild (29.3% vs 35.4%, P < .001), moderate (4.0% vs 6.8%, P < .001), or severe abnormalities (5.7% vs 8.3%, P < .001) found on NIT. Women were less likely to be referred for catheterization than men (7.6% vs 12.6%, adjusted OR 0.75 [0.62-0.90]; P = .002). Of those who underwent catheterization within 90 days of randomization (358 women, 534 men), fewer women than men had obstructive coronary artery disease (40.8% vs 60.9%, P < .001). At a 60-day visit, women were significantly less likely than men to report statin use when indicated (adjusted OR 0.81 [0.73-0.91]; P < .001) but were similarly likely to report aspirin use when indicated (adjusted OR 0.78 [0.56-1.08]; P = .13). Over a median follow-up of 25 months, women had better outcomes than men (adjusted OR 0.73 [0.57-0.94]; P = .017).

conclusionsAlthough women more frequently had normal NITs compared with men, those with abnormalities on NIT were less likely to be referred for catheterization or to receive statin therapy. The high rates of negative NIT in women, coupled with the better outcomes compared with men, strongly support the need for a sex-specific algorithm to guide NIT and chest pain management.

Indexed as

Sex FactorsAspirinCardiac CatheterizationComputed Tomography AngiographyCoronary AngiographyCoronary Artery DiseaseExercise TestFemaleFibrinolytic AgentsHumansHydroxymethylglutaryl-CoA Reductase InhibitorsLogistic ModelsMaleMiddle AgedTime FactorsTreatment OutcomeAspirinFibrinolytic AgentsHydroxymethylglutaryl-CoA Reductase Inhibitors

Identifiers

PMID30529930
PMCPMC6382571
OpenAlexW2899917974

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.